Professional Seasonal Analysis for Trading

Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT)

Seasonality Analysis

Stocks 19 Years Analyzed

Lixte Biotechnology Holdings, Inc. - Common Stock Annual Seasonality Statistics

65.06%
Avg Annual Return
37.3%
Avg Monthly Win Rate
7/12
Positive Months
19
Years Analyzed

Lixte Biotechnology Holdings, Inc. - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January 6.29%
37%
Weak
February 13.89%
47%
Weak
March 10.30%
47%
Weak
April WORST -13.99%
26%
Very Weak
May 10.35%
50%
Weak
June -3.95%
39%
Very Weak
July 20.96%
50%
Weak
August 17.19%
33%
Weak
September -3.93%
28%
Very Weak
October -10.12%
32%
Very Weak
November BEST 28.63%
37%
Weak
December -10.57%
21%
Very Weak

Lixte Biotechnology Holdings, Inc. - Common Stock 2026 vs Historical Pattern

Current Position
44.67
Historical Avg Position
36.82
Deviation
+7.84
Performance
Above Average

Lixte Biotechnology Holdings, Inc. - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for LIXT with overlay patterns, custom date ranges, and more.

Create Free Account

Lixte Biotechnology Holdings, Inc. - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Lixte Biotechnology Holdings, Inc. - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for LIXT across multiple timeframes.

Create Free Account

About Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT) Seasonality

Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT) has been analyzed using 19 years of historical data to identify seasonal patterns. Classified under Stocks, Lixte Biotechnology Holdings, Inc. - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Lixte Biotechnology Holdings, Inc. - Common Stock is historically November, with an average return of 28.63% and a win rate of 37%. Conversely, April tends to be the weakest month, averaging -13.99% return.

Looking at the full calendar year, Lixte Biotechnology Holdings, Inc. - Common Stock has an average annual return of 65.06% with an overall monthly win rate of 37.3%. Out of 12 months, 7 typically show positive average returns.

The seasonal pattern for Lixte Biotechnology Holdings, Inc. - Common Stock has a consistency score of 28.8 (Poor), based on 20 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Lixte Biotechnology Holdings, Inc. - Common Stock Seasonality FAQ

What is the best month to buy Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT)?

Historically, November has been the best month for Lixte Biotechnology Holdings, Inc. - Common Stock, with an average return of 28.63% and a win rate of 37%. However, past performance does not guarantee future results.

What is the worst month for Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT)?

Based on historical data, April has been the weakest month for Lixte Biotechnology Holdings, Inc. - Common Stock, with an average return of -13.99%. This is a historical observation and does not guarantee future results.

How reliable is LIXT seasonality data?

The seasonality analysis for Lixte Biotechnology Holdings, Inc. - Common Stock is based on 19 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Lixte Biotechnology Holdings, Inc. - Common Stock seasonality in my trading?

Use Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.